The Food and Drug Administration has accused Patrick Soon-Shiong and his biotech company ImmunityBio of making false and misleading claims about a cancer treatment. Soon-Shiong, described as a controversial figure in the biotech industry, faces formal allegations from the federal regulator.
The FDA's action represents a significant regulatory rebuke for Soon-Shiong, who has been a prominent but polarizing figure in biotechnology and pharmaceutical development. Such accusations from the FDA typically indicate serious concerns about public health and patient safety.